Glenmark Pushes Back On US Price-Fixing Charges
DoJ Allegations Filed Against Firm Include Pravastatin Collusion With Apotex
Glenmark has issued a forceful rebuttal over US price-fixing charges being pursued by the country’s Department of Justice covering drugs such as pravastatin.
You may also be interested in...
Glenmark reports challenging first quarter across key markets amid the pandemic, with US momentum impacted in part by pricing pressure in the dermatology segment. New product flows could restore uptick in that market, though US approval for rhinitis therapy Ryaltris is anticipated only in the second half of 2021.
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
A third major price-fixing lawsuit has been filed in the US, naming over two dozen companies and ten individuals in allegations covering 80 generic presentations, focusing in particular on topical drugs.